Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

NCT02364206 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT02364206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02364206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Lead sponsor
Centre Jean Perrin
Phase
Phase 1/2
Overall status
Completed
Start date
June 8, 2015
Completion date
August 31, 2019
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adult glioblastoma